[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haploidentical-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haploidentical-hematopoietic-stem-cell-transplantation":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,63,88],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644427",false,"NCT07662382","Cousin vs. Sibling Donors in Haplo-HSCT","Comparison of Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation From Cousin Donors Versus Sibling Donors in Patients With Hematological Malignancies: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)\n* Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024\n* Documented exact date of transplantation available in medical charts\n* Verifiable donor kinship classified as either cousin or sibiling\n* Complete longitudinal follow-up data accessible for outcome assessment\n\nExclusion Criteria:\n\n* Prior receipt of any form of hematopoietic stem cell transplantation\n* An age difference of more than 18 years between the donor and recipient\n* Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.\n\nThe main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.\n\nStudy participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.",[23,24,25],"Hematopoietic Malignancies","Haploidentical Hematopoietic Stem Cell Transplantation","Donor","NOT_YET_RECRUITING","2026-06-16",{"date":29,"type":30},"2026-06-23","ACTUAL",{"date":32,"type":19},"2026-08-01",{"date":34,"type":19},"2027-10-31",{"name":36,"class":37},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":47,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":50,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":38},"100519311","NCT06041893","Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide","Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide","Inclusion Criteria:\n\n* Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.\n\nExclusion Criteria:\n\n* A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.",{"count":46,"type":19},20,"1 Year","Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.",[24],[51,52],"post transplant cyclophosphamide","antithymocyte globulin","RECRUITING","2024-12-02",{"date":56,"type":30},"2024-12-03",{"date":58,"type":30},"2023-05-29",{"date":60,"type":19},"2025-12-31",{"name":62,"class":37},"Samsung Medical Center",{"id":64,"slug":4,"hasResults":10,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":10,"sex":15,"minAge":69,"maxAge":16,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":38},"100548602","NCT06423131","Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT","TCRαβ+ Cell Deleted Versus Traditional Haploidentical Hematopoietic Stem Cell Transplantation ：A Single-center, Prospective, Non-randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Age 8 weeks to 18 years\n* Children who meet the indicators haploidentical hematopoietic cell transplantation\n* No HLA ≥ 9\u002F10 donor or not suitable for this type of donor due to illness\n* Informed consent must be signed (by the patient or legal representative)\n\nExclusion Criteria:\n\n* Liver function abnormalities with bilirubin \\>2 mg\u002FdL and elevation of transaminases higher than 400 U\u002FL\n* Chronic active viral hepatitis\n* Ejection fraction \\\u003C50%\n* Respiratory failure necessitating supplemental oxygen\n* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study\n* Patients unwilling or unable to comply with the protocol or unable to give informed consent\n* Concurrent severe or uncontrolled infection","8 Weeks",{"count":71,"type":19},110,"INTERVENTIONAL",[74],"NA","This is a single-center prospective, non-randomized controlled clinical study in China using CliniMACS TCRα\u002Fβ+ cell depleted stem cell haploidentical donors versus conventional Beijing protocol for haploidentical hematopoietic stem cell transplantation in children.",[77,78,79,24],"Graft-Versus-Host Disease","Hematopoietic Stem Cell Transplantation","Child, Only","2024-05-26",{"date":82,"type":30},"2024-05-29",{"date":80,"type":30},{"date":85,"type":19},"2028-03-31",{"name":87,"class":37},"Sijia Gu",{"id":89,"slug":4,"hasResults":10,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":72,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":38},"100545431","NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)",{"count":95,"type":19},146,[97],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[100,24,101],"Acute T Cell Lymphoblastic Leukemia","Cord Blood","2024-04-24",{"date":104,"type":30},"2024-04-26",{"date":106,"type":30},"2024-04-01",{"date":85,"type":19},{"name":36,"class":37},""]